Abstract 329P
Background
Osimertinib is a 3rd generation, irreversible, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with CNS activity; it is the preferred 1L treatment in pts with EGFR-TKI-sensitising (EGFRm) advanced NSCLC. However, pts on 1L osimertinib may develop treatment resistance, commonly by secondary EGFR alterations. The ongoing Phase II ORCHARD platform study (NCT03944772) aims to characterise these resistance mechanisms and identify novel 2L combinations. Preclinical data demonstrated antitumour activity when combining osimertinib with an anti-EGFR monoclonal antibody (mAb). Here we report an interim analysis of safety and efficacy of osimertinib + necitumumab, a mAb that blocks the ligand binding site of EGFR, in pts with EGFRm advanced NSCLC and a secondary EGFR alteration post 1L osimertinib.
Methods
Pts with a secondary alteration in EGFR (amplification, L718 or G724 mutation, exon 20 insertion) determined by next generation sequencing on tissue collected post disease progression on 1L osimertinib, received osimertinib (80 mg, orally, once daily) + necitumumab (800 mg intravenously on Day 1 + 8 of a 3-week cycle). Primary endpoint: objective response rate (ORR); other endpoints: safety. Futility criterion was defined as <10% chance ORR is ≥45%. Data cutoff (DCO): 11 Feb 2022.
Results
Sixteen pts were treated (56% ≥65 years, 63% male, 63% white, 61% never smokers). At DCO, 11 pts (69%) had discontinued treatment and 13 were evaluable for confirmed response. ORR was 15% (n=2 confirmed partial responses, 80% CI 4.2, 36.0). Stable disease was reported in 5 pts (39%) and progressive disease in 5 pts (39%); 1 pt (8%) was non-evaluable. Recruitment was closed as futility criteria were met. Overall, 7/16 (44%) had one or more Grade ≥3 adverse event (AE); 5 (31%) had serious AEs, 2 (13%) had an AE with an outcome of death, 1 was possibly related to necitumumab. No cases of interstitial lung disease seen.
Conclusions
Osimertinib + necitumumab showed no new safety signals in this population; however, futility criterion was met and recruitment was closed. These results suggest that this combination may not have the requisite clinical activity for further clinical development in this pt population.
Clinical trial identification
NCT03944772.
Editorial acknowledgement
The authors would like to acknowledge Annie Mellings, MSc, of Ashfield MedComms, an Inizio company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).
Legal entity responsible for the study
AstraZeneca.
Funding
This study (NCT03944772) was funded and sponsored by AstraZeneca. Necitumumab was provided by the manufacturer Eli Lilly for inclusion in this study.
Disclosure
J.W. Riess: Financial Interests, Institutional, Research Grant: Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Revolution Medicines; Financial Interests, Personal, Advisory Role, Consultation fees: Novartis, Blueprint; Financial Interests, Personal, Advisory Board: BeiGene, Daiichi Sankyo, EMD Serano, Jazz Pharmaceuticals, Janssen, Turning Point, Bristol Myers Squibb, Roche/Genentech, Boehringer Ingelheim, Regeneron. J.A. De Langen: Financial Interests, Personal, Advisory Role: AstraZeneca, BMS, Boehringer Ingelheim, Pfizer, Roche, Lilly, MSD; Financial Interests, Personal, Research Grant: AstraZeneca, BMS, Boehringer Ingelheim, MSD. Z. Piotrowska: Financial Interests, Personal, Research Grant: Novartis, Takeda, Spectrum, AstraZeneca, Tesaro/GSK, Cullinan, Daiichi Sankyo, AbbVie, Janssen, Blueprint; Financial Interests, Personal, Advisory Role, Consulting fees: Janssen, AstraZeneca, Eli Lilly, Takeda, Daiichi Sankyo, Cullinan, C4 Therapeutics, Jazz, Blueprint. S.B. Goldberg: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Blueprint Medicine, Sanofi Genzyme, Daiichi Sankyo, Regeneron, Takeda; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Research Grant: AstraZeneca, Boehringer Ingelheim, Mirati Therapeutics. J.W. Goldman: Financial Interests, Personal, Other, Honoraria: AstraZeneca, BMS, Genentech, Pfizer; Financial Interests, Institutional, Research Grant: Advaxis, Array, AstraZeneca, BMS, Eli Lilly, Genentech/Roche, G1 Therapeutics, Merck, Pfizer; Financial Interests, Personal, Other, Travel support: AstraZeneca. I. Okamoto: Financial Interests, Personal, Advisory Role: AstraZeneca, Chugai Pharma, AbbVie; Financial Interests, Personal, Other, Honoraria: AstraZeneca, Taiho Pharmaceutical, Ono Pharmaceutical, MSD Oncology, Bristol Myers Squibb, Chugai Pharma, Pfizer; Financial Interests, Personal, Research Grant: Boehringer Ingelheim, AstraZeneca, Taiho Pharmaceutical, Ono Pharmaceutical, MSD Oncology, Astellas Pharma, Bristol Myers Squibb, Chugai Pharma, AbbVie. S. Ponce Aix: Financial Interests, Personal, Research Grant: Roche, MSD; Financial Interests, Personal, Other, Lectures: Roche, MSD, BMS, AstraZeneca, Pfizer. S. Teraoka: Financial Interests, Personal, Advisory Role: Pfizer Inc.; Financial Interests, Personal, Speaker’s Bureau: Chugai Pharma, Novartis, AstraZeneca, Taiho Pharmaceutical, Ono Pharmaceutical Co.,Ltd. H. Ambrose, J. Maidment, B. Merchan Ruiz: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. K.H. Tang, N. Hewson: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. J. Cosaert: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Project Lead: Orchard, Hudson. H.A. Yu: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Janssen, Blueprint Medicine, C4 Therapeutics, Daiichi, Black Diamond, Cullinan; Financial Interests, Institutional, Research Grant: AstraZeneca, Pfizer, Lilly, Cullinan, Novartis, Daiichi, Janssen, Blueprint, ERASCA.
Resources from the same session
364P - Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
Presenter: Azura Ahmad
Session: Poster viewing 05.
365P - Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
Presenter: Alexandra Schuler
Session: Poster viewing 05.
366P - EGFR amplification is a putative resistance mechanism for NSCLC-LM patients with TKI therapy and is associated with poor outcome
Presenter: Hainan Yang
Session: Poster viewing 05.
367P - High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE
Presenter: Yun Fan
Session: Poster viewing 05.
368P - A special Imaging pattern of bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs
Presenter: Zhen-Bang Gu
Session: Poster viewing 05.
370P - Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Presenter: Fang Cun
Session: Poster viewing 05.
371P - Real-world data of first-line treatment with aumolertinib for elderly EGFR+ NSCLC patients
Presenter: Haitao Zhang
Session: Poster viewing 05.
373P - Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
Presenter: WenFeng Fang
Session: Poster viewing 05.